How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults.
William B SlaytonKirk R SchultzLewis B SilvermanStephen P HungerPublished in: Pediatric blood & cancer (2020)
Treatment for children with Philadelphia chromosome-positive acute lymphoblastic leukemia has changed radically over the past 20 years. This type of leukemia used to have dismal prognosis, but today cure rates have improved with combination of cytotoxic chemotherapy and a tyrosine kinase inhibitor such as imatinib or dasatinib, with hematopoietic stem cell transplant reserved for patients who are at high risk based on slow response to therapy or who relapse. Treating these patients can be challenging particularly if they are not enrolled on a clinical trial. Here, we describe our approach to these patients.
Keyphrases
- acute lymphoblastic leukemia
- young adults
- end stage renal disease
- clinical trial
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- squamous cell carcinoma
- randomized controlled trial
- stem cells
- gene expression
- acute myeloid leukemia
- copy number
- allogeneic hematopoietic stem cell transplantation
- dna methylation
- bone marrow
- chronic myeloid leukemia
- patient reported
- open label
- phase ii